IPP Bureau
Bristol Myers Squibb prices €5 billion senior unsecured notes offering
By IPP Bureau - November 10, 2025
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
By IPP Bureau - November 10, 2025
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies expands ASEAN presence with new drug approvals in Vietnam
By IPP Bureau - November 10, 2025
Venus Remedies now has 29 active product approvals in Vietnam alone
Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'
By IPP Bureau - November 10, 2025
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Novo Nordisk India partners with Emcure to commercialise Poviztra in India
By IPP Bureau - November 10, 2025
Poviztra is a second brand of Wegovy
Glenmark secures China approval for Ryaltris
By IPP Bureau - November 10, 2025
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Marksans Pharma's Goa unit clears FDA inspection
By IPP Bureau - November 10, 2025
The said inspection concluded with Zero Form 483 observation
Poly Medicure posts Q2 FY26 consolidated net profit at Rs. 91.83 Cr
By IPP Bureau - November 09, 2025
Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025
Syngene International reports Q2 FY26 consolidated PAT at Rs. 67.1 Cr
By IPP Bureau - November 09, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr
By IPP Bureau - November 09, 2025
Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025
Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr
By IPP Bureau - November 09, 2025
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr
By IPP Bureau - November 09, 2025
Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025
SMS Pharmaceuticals post Q2 FY26 consolidated PAT at Rs. 25.31 Cr
By IPP Bureau - November 09, 2025
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
Sun Pharmaceutical Industries posts consolidated Q2 FY26 PAT higher at Rs. 3,137.09 Cr
By IPP Bureau - November 08, 2025
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Zydus Lifesciences secures FDA tentative approval for Olaparib tablets
By IPP Bureau - November 08, 2025
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
